Properties of measurements obtained during cardiopulmonary exercise testing in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
Properties of measurements obtained during cardiopulmonary exercise testing in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Davenport, Todd E, Stevens, Staci R, Stevens, Jared et al. · Work (Reading, Mass.) · 2020 · DOI
Quick Summary
Researchers tested whether a standard exercise test (cardiopulmonary exercise test, or CPET) could reliably measure how ME/CFS affects the body's ability to exercise. They had 51 women with ME/CFS and 10 healthy women do the same exercise test twice, 24 hours apart. The results showed that the measurements were consistent and clearly different between the two groups, suggesting that CPET could be a useful tool for assessing ME/CFS.
Why It Matters
CPET measurements could serve as an objective biomarker for ME/CFS, helping clinicians diagnose the condition and assess disease severity in a standardized, reproducible way. This is particularly important because ME/CFS currently lacks specific laboratory tests, making reliable physiological measurements valuable for both patient care and research.
Observed Findings
CPET measurements showed moderate-to-high reliability in ME/CFS patients across two tests performed 24 hours apart.
All cardiac, pulmonary, and metabolic measurements showed moderate-to-large effect sizes when comparing ME/CFS patients to control subjects.
Minimum detectable change values were generally larger for ME/CFS patients than control subjects.
Coefficients of variation for CPET measurements were comparable between ME/CFS and control groups.
CPET measurements demonstrated adequate responsiveness for detecting meaningful changes in individual patients.
Inferred Conclusions
CPET is a reproducible tool for measuring the physiological impact of ME/CFS on exercise capacity.
CPET measurements can reliably distinguish between people with ME/CFS and sedentary controls.
CPET has adequate sensitivity to detect clinically meaningful changes in individual patients over time.
CPET measurements have properties suitable for use as research endpoints and clinical assessment tools in ME/CFS.
Remaining Questions
Do CPET findings differ in male patients with ME/CFS, or in patients from different demographic backgrounds?
What This Study Does Not Prove
This study does not establish that abnormal CPET results cause ME/CFS symptoms or explain the underlying mechanisms of the disease. The study's reliability estimates are based on a relatively small sample of females only, so findings may not generalize to male patients or diverse demographic groups. Additionally, while CPET measurements are consistent and different between groups, the study does not establish whether CPET can predict treatment response or clinical outcomes.